Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

The drug is a generic form of the highly successful Alimta.

Teva Pharmaceuticals Unit Actavis Generics Wins FDA Approval for Lung Cancer Drug Pemetrexed

Allergan

The DFS charges claim that Teva (TEVA) and Allergan (AGN) used fraudulent marketing and promotional campaigns to promote their opioid products

Opioid Crisis Deepens as Teva, Allergan Face Fraud Charges

Teva Kicked In Its Back

MONTRÉAL, Québec--(BUSINESS WIRE)--Teva Canada announces product availability of AJOVY™.

Teva Canada Announces Product Availability of AJOVY™

Two of the company's business units stand accused of improperly assisting Medicare recipients through proxies.

U.S. Government Sues Teva Pharmaceutical for Alleged Drug Kickbacks

Kohl's

The S&P 500 joined the Nasdaq at all-time highs.

Stock Markets Hit New Records; Retail Stocks, Teva Take Hits

The United States is suing the drugmaker. Again.

Here's Why Teva Pharmaceutical Fell as Much as 15.4% Today

New York Governor Andrew Cuomo said on Tuesday the State Department of Financial Services had filed charges against Teva Pharmaceuticals and Allergan Plc over their role in the opioid crisis.

New York files insurance fraud charges against opioid makers Teva, Allergan

Shares of Teva Pharmaceutical Industries Ltd. TEVA, -10.68% tumbled 10.9% in trading on Tuesday after the U.S.

Teva's stock sinks 10% on False Claims allegations

Booz Allen Hamilton Hld

Huntington Ingalls Industries

ManpowerGroup

Newcrest Mining Ltd

Raytheon Technologies

Sony

Smith & Wesson Brands

AgEagle Aerial Systems

The devastation of the coronavirus was the last straw for the Trump administration, prompting an aggressive approach to U.S.-China relations.

9 Companies to Invest In as U.S.-China Relations Deteriorate

Cars.com

Ford Motor Company

Identiv

Kinross Gold

LiveXLive Media

Limelight Networks

Monopar Therapeutics

Due to the disjointed fundamentals, many investors were caught off guard with this current bull market. However, there are cheap stocks to buy that are still available.

8 Cheap Stocks to Keep on Your Short List

Johnson & Johnson

AbbVie

These pharmaceutical giants are already preparing for the possibility of medical marijuana legalization.

3 Big Pharma Stocks With Surprising Cannabis Connections

Sirius XM Holdings Inc

AT&T

Wells Fargo

You don't need to start with a fortune to make one on Wall Street.

Got $50? Here Are 4 Great Stocks to Buy Now

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported strong quarterly results, prompting an analyst at Barclays to upgrade the stock.

Teva's Litigation Risks Weigh Against Stabilizing Fundamentals, Analyst Says

Teva (TEVA) beats second-quarter estimates for earnings while missing the same for sales. It maintains its previously issued guidance for 2020.

Teva (TEVA) Q2 Earnings Top, Stock Up Despite Coronavirus Woes

Teva Pharmaceutical Industries Limited (TEVA) CEO Kare Schultz on Q2 2020 Results - Earnings Call Transcript

Teva beats estimates for earnings while missing the same for sales in second-quarter 2020. It maintains its previously issued guidance for 2020.

Teva (TEVA) Q2 Earnings Beat, Sales Miss, Keeps 2020 View

Israel-based Teva Pharmaceutical Industries reported a slightly smaller than-expected fall in second-quarter profit on Wednesday, as higher profitability in North America partially offset lower profit margins in Europe.

Teva Pharm second-quarter profit slightly beats profit forecast

TEL AVIV, Israel & REYKJAVIK, Iceland--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and biopharmaceutical company Alvotech today announced that they have entered into an exclusive strategic partnership for the commercialization in the U.S.

Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended June 30, 2020.

Teva Reports Second Quarter 2020 Financial Results

On Teva's (TEVA) second-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products

Teva (TEVA) to Report Q2 Earnings: What's in the Cards?

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), who holds (through its Japanese affiliates) with Takeda a joint business venture (the "BV") in the Japanese market, announced today a new strategy for its local commercial operations.

Teva Announces New Strategic Focus in the Japanese Market

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced Otsuka Pharmaceutical Co.

Teva Announces New Drug Application Filing in Japan for AJOVY® (fremanezumab) Injection

Teva Putting Its Troubles Behind, Why The Stock Is Cheap And I'm Long

CVS Health

Exxon Mobil

These brand-name companies are big-time bargains for patient investors.

News for Teva Pharmaceutical Stock (TEVA)